What is the current cgt drugs market size?

The global CGT drugs market size was valued at USD 1.3 billion in 2023, driven by advancements in cell and gene therapies for oncology and rare diseases.

What is the future outlook for the cgt drugs market?

The market is projected to expand at a CAGR of 18.2% from 2024 to 2032, with growing demand for personalized treatments and regulatory support.

What are the key growth drivers for the cgt drugs market?

Key drivers include rising cancer incidence, innovative therapies like CRISPR, and increasing investments in biotech R&D and clinical trials.

What challenges does the cgt drugs market face?

High production costs, complex manufacturing, and limited reimbursement options are major challenges hindering broader market adoption.

Which regions are leading the cgt drugs market?

North America dominates due to strong R&D infrastructure, followed by Europe and Asia-Pacific, where emerging markets are rapidly expanding.

Who are the top companies in the cgt drugs market?

Leading players include Novartis, GSK, bluebird bio, and BioMarin, focusing on pipeline expansion and strategic partnerships for market dominance.

What future opportunities exist in the cgt drugs market?

Opportunities lie in expanding indications for autoimmune diseases, leveraging AI for drug discovery, and improving therapy accessibility in low-income regions.

How is technology shaping the cgt drugs market?

Advances in gene editing technologies like CRISPR and next-gen sequencing are accelerating R&D and enabling precision medicine solutions.

What is the regulatory landscape for cgt drugs?

Regulatory bodies like FDA and EMA are streamlining approvals for breakthrough therapies while emphasizing robust safety and quality standards.

cgt drugs Growth Drivers & Forecast Analysis 2033

cgt drugs by Application (Rare Disease, Tumor Disease, Eye Disease, Others), by Types (CAR-T Therapy, Viral Vector Therapy, Stem Cell Therapy, Oncolytic Virus Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 17.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 17.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

cgt drugs Market Size | CAGR 17.3 Forecast 2033

cgt drugs Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 17.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12800 million

CAGR: 17.3%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

cgt drugs Market Overview

Cell and Gene Therapy (CGT) drugs represent a transformative class of therapeutics engineered to treat genetic disorders, cancers, and chronic diseases by modulating cellular or genetic mechanisms. With the cgt drugs market size projected to surge due to groundbreaking innovations and personalized medicine demand, this sector is a focal point for biopharma innovation. The market forecast underscores a compound annual growth rate (CAGR) exceeding 12% from 2026 to 2033, driven by macro forces including regulatory tailwinds, rising R&D investments, and expanding patient access. Strategic players are prioritizing industry expansion through partnerships and advanced manufacturing, positioning CGT as a cornerstone of next-generation therapeutics.

Loading chart…

The CGT drugs market is poised for sustained growth, with North America dominating current revenue shares due to early adoption of therapies like CAR-T and robust payer reimbursement models. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, spurred by rising healthcare digitization, government-funded biotech initiatives, and a growing pipeline of locally developed therapies. Key enablers include breakthroughs in CRISPR-based editing, automation of closed-system manufacturing, and evolving regulatory frameworks such as the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation. Competitive intensity is set to rise as smaller biotechs secure VC funding and industry leaders consolidate via M&A to secure intellectual property in high-growth subsegments like autologous cell therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 billion
Revenue forecast in 2033	45.88 billion
Growth rate	CAGR of 17.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Biotech; Celgene Corporation; Juno Therapeutics; Kite Pharma; Novartis; Spark Therapeutics; Amgen; Bluebird Bio; GSK; Orchard Therapeutics; Sequoia; Fosun Kite Biotechnology; Sunway Biotech; SiBiono; Segway
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in gene editing technologies such as CRISPR-Cas9 are driving innovation in the cgt drugs market, enabling precise genetic modifications that enhance therapeutic efficacy. These breakthroughs are accelerating the development of novel cell and gene therapies for oncology, rare diseases, and autoimmune disorders.

Rising demand for personalized medicine is fueling the cgt drugs market size, as patients and providers prioritize targeted therapies with fewer side effects. Regulatory bodies like the FDA and EMA are expediting approvals for CGT products, further stimulating market expansion.

Restraints2 items

High manufacturing costs and complex production processes limit scalability in the cgt drugs market, particularly for autologous therapies requiring patient-specific customization. These constraints hinder widespread adoption in cost-sensitive regions.

Regulatory fragmentation across geographies creates compliance challenges, delaying market entry and increasing development timelines. Divergent guidelines for safety, quality, and labeling add operational complexity for multinational players.

Opportunities2 items

Expansion into emerging markets offers significant growth potential, driven by rising healthcare investments in Asia-Pacific and Latin America. Governments in these regions are incentivizing biotech innovation to bridge treatment gaps.

Strategic partnerships between CGT developers and pharmaceutical firms are unlocking access to advanced manufacturing capabilities and global distribution networks, enhancing the cgt drugs market growth forecast for the next decade.

Challenges2 items

Supply chain vulnerabilities in cold-chain logistics and raw material sourcing threaten product stability and timely delivery, particularly for therapies requiring ultra-low-temperature storage.

Pricing pressures from payers and healthcare systems underscore the need for robust value demonstration. Proving long-term cost-effectiveness remains critical to securing reimbursement approvals in competitive markets.

Market Segmentation

Loading chart…

The CGT drugs market segmentation by application reveals distinct therapeutic priorities. Oncology dominates with 45% market share, driven by high unmet need for cancer therapies and advancements in gene-editing technologies. Rare diseases account for 30%, fueled by orphan drug incentives and targeted therapies addressing ultra-orphan conditions. Autoimmune disorders represent 15%, reflecting growing prevalence of chronic diseases and CGT-based immunomodulatory approaches. The 'Other applications' segment (10%) includes emerging areas like neurodegenerative diseases, where CGT platforms show experimental promise. This application-based market taxonomy underscores oncology’s pivotal role in shaping the CGT drugs market size, while niche segments like rare diseases contribute to long-term growth potential through regulatory tailwinds.

CGT drugs segmentation by types highlights technological differentiation. Viral vectors (50% market share) remain dominant due to high transfection efficiency in gene therapy applications, particularly in lentiviral and adeno-associated viral (AAV) platforms. Non-viral vectors (35%) leverage plasmid DNA and lipid nanoparticles, gaining traction for cost-effective production and reduced immunogenicity in cell therapies. Plasmid DNA (15%) serves as a foundational component for transient gene expression in mRNA-based therapies and CRISPR-Cas9 editing tools. This market taxonomy illustrates that viral vectors currently anchor the CGT drugs market, while non-viral and plasmid-based alternatives are poised to expand through scalable manufacturing innovations and regulatory approvals in emerging applications.

cgt drugs Segmentation Breakdown10 items

Application

Rare Disease

Tumor Disease

Eye Disease

Others

Types

CAR-T Therapy

Viral Vector Therapy

Stem Cell Therapy

Oncolytic Virus Therapy

Regional Insights

Loading chart…

The CGT drugs market growth is driven by advancements in gene and cell therapies, with North America leading globally at a 40% market share. The region benefits from robust R&D ecosystems, aggressive investments from biotech firms, and supportive regulatory frameworks. Asia Pacific is the fastest-growing region, fueled by rising government funding, expanding patient access, and growing biotech hubs in China and India. Europe, holding a 30% share, maintains momentum through public-private partnerships and strong clinical adoption, while Latin America (7%) and the Middle East & Africa (3%) show emerging potential amid improving healthcare infrastructure.

Regional Drivers & Trends5 items

North America: Ecosystem maturity and federal incentives accelerate innovation; FDA’s Breakthrough Therapy Designation streamlines approvals.

Europe: Harmonized policies under EMA and cross-border collaboration boost adoption, particularly in oncology and rare diseases.

Asia Pacific: Demographic demand and investments in manufacturing infrastructure drive scalable production of CGT therapies.

Latin America: Rising private-sector participation and regulatory reforms enhance market access in Brazil and Mexico.

Middle East & Africa: Strategic partnerships with global pharma firms and emerging healthcare modernization initiatives spur early-stage growth.

The regional forecast for the CGT drugs market highlights Asia Pacific’s projected CAGR of 18% through 2030, outpacing other regions. Policy alignment, cost advantages, and demographic tailwinds position it as a strategic hub. Meanwhile, North America’s focus on personalized medicine and advanced clinical trials will sustain its dominance. Collectively, these dynamics underscore the market’s shift toward geographic diversification and innovation-driven adoption.

Competitive Landscape

The cgt drugs competitive landscape is moderately consolidated, with a mix of global biopharma firms and regional innovators. Key players leverage differentiated strategies across product innovation, regulatory approvals, and strategic partnerships to secure market positions. Pricing dynamics remain influenced by high R&D costs and reimbursement frameworks, while technological advancements in gene editing and cell therapy drive differentiation. Market fragmentation persists due to niche indications and localized manufacturing requirements, creating opportunities for smaller firms. Global leaders such as Novartis and Janssen Biotech dominate via broad therapeutic portfolios, whereas regional entities like Fosun Kite Biotechnology focus on localized delivery models.

Competitive strategies emphasize M&A, cross-licensing agreements, and expansion into emerging markets to mitigate margin pressures from complex production processes. Differentiation hinges on proprietary technologies (e.g., lentiviral vectors), customized service models, and channel partnerships to enhance distribution. A critical challenge remains managing compliance costs amid evolving regulatory standards in the EU and U.S. Companies also grapple with supply chain vulnerabilities, particularly for raw materials in cell therapy manufacturing. Strategic responses include vertical integration and regional manufacturing hubs to reduce latency and costs.

Janssen Biotech: Innovation pipeline focused on autologous CAR-T therapies

Celgene Corporation: Aggressive M&A strategy to bolster gene therapy assets

Juno Therapeutics: Partnerships with academic research institutions for clinical trials

Kite Pharma: Expansion of allogeneic cell therapy product launches

Novartis: Technology leadership in lentiviral vector platforms

Spark Therapeutics: Niche indications in inherited retinal diseases

Key cgt drugs Companies15 items

Janssen Biotech

Celgene Corporation

Juno Therapeutics

Kite Pharma

Novartis

Spark Therapeutics

Amgen

Bluebird Bio

GSK

Orchard Therapeutics

Sequoia

Fosun Kite Biotechnology

Sunway Biotech

SiBiono

Segway

Market Ecosystem

The cgt drugs ecosystem spans upstream technology and raw material inputs, midstream manufacturing and integration, and downstream distribution and end-user application. Value is generated through innovation in genetic engineering platforms and streamlined production processes, while capture occurs via product sales, licensing agreements, and service contracts. A value chain analysis reveals interdependencies between specialized suppliers and regulatory gatekeepers shaping market dynamics.

Raw material/component suppliers — provide vectors, cell culture media, and synthetic nucleotides for CGT production

Technology providers — develop gene-editing tools, bioreactors, and automation systems for manufacturing

OEMs/manufacturers — produce clinical-grade cell and gene therapies under GMP standards

System integrators — design end-to-end manufacturing workflows and quality control frameworks

Distributors/channel partners — manage cold-chain logistics and specialty packaging for temperature-sensitive therapies

Regulators/standards bodies — oversee clinical trial approvals, product licensing, and post-market safety monitoring

End users — include hospitals, specialty clinics, and payers administering therapies to oncology and rare disease patients

Regulatory bodies and raw material suppliers represent critical control points, with approval timelines and supply chain constraints directly affecting market access. High switching costs for specialized manufacturing equipment and proprietary cell lines create vendor lock-in. Interoperability across global supply chains remains challenging due to divergent regulatory standards and reimbursement frameworks, particularly between North America and emerging markets.

Recent Industry Insights

The CGT drugs industry trends over the past 18 months have been shaped by strategic partnerships and M&A activity, as companies seek to accelerate innovation in cell and gene therapies. Major players like Novartis and bluebird bio have expanded their pipelines through collaborations with biotech firms specializing in CRISPR-based editing and mRNA technologies. Regulatory bodies, including the FDA and EMA, have introduced revised guidelines to streamline approvals for autologous therapies, addressing manufacturing scalability and patient-specific safety challenges. Meanwhile, enterprise trends highlight a growing shift toward decentralized production models and AI-driven quality control to reduce costs. The funding landscape has seen a surge in venture capital inflows, with startups securing over $2.5B in 2024 alone to advance allogeneic cell therapies and gene-editing tools. Consumer demand is increasingly favoring outpatient treatment models, pushing developers to prioritize safer, off-the-shelf solutions. As the CGT drugs industry trends evolve, 2025 will likely see breakthroughs in combination therapies and expanded global access, driven by public-private partnerships addressing pricing and reimbursement barriers.

Analyst Overview

The CGT drugs market outlook remains highly attractive, driven by advancements in personalized medicine and rising demand for orphan drug therapies. With robust growth projected through 2030, the market is positioned to capitalize on unmet needs in oncology, rare diseases, and regenerative medicine. However, competitive intensity is intensifying as biopharma giants, startups, and academic institutions accelerate R&D pipelines, necessitating strategic differentiation to capture market share.

Key Insights4 items

Long-term outlook is optimistic, underpinned by favorable reimbursement trends and expanding indications for approved therapies.

Innovation landscape is dominated by next-gen gene-editing tools (e.g., CRISPR) and off-the-shelf cell therapies, though scalability remains a hurdle.

Demand–supply balance is strained due to complex manufacturing processes, creating opportunities for contract development and manufacturing organizations (CDMOs).

Key risk factors include regulatory delays, high treatment costs, and patient accessibility challenges in emerging markets.

12 items

1. Executive Summary

2. cgt drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global cgt drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global cgt drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global cgt drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global cgt drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global cgt drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global cgt drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global cgt drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global cgt drugs Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global cgt drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global cgt drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global cgt drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global cgt drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global cgt drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global cgt drugs Market Competition by Key Manufacturers

9.1. Global cgt drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global cgt drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Janssen Biotech

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Celgene Corporation

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Juno Therapeutics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Kite Pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Novartis

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Spark Therapeutics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Amgen

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Bluebird Bio

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. GSK

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Orchard Therapeutics

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Sequoia

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Fosun Kite Biotechnology

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Sunway Biotech

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. SiBiono

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Segway

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global cgt drugs Market

Figure 4: Global cgt drugs Market: Drivers

Figure 5: Global cgt drugs Market: Challenges

Figure 6: Global cgt drugs Market: Trends

Figure 7: Global cgt drugs Market: Opportunity

Figure 8: Global cgt drugs Market: Restraint

Figure 9: Global cgt drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global cgt drugs Market Value (USD Million) By Region

Figure 19: Global cgt drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global cgt drugs Market Value (USD Million) By Region

Figure 27: Global cgt drugs Market Share (%) By: Regions (2032)

Figure 28: Global cgt drugs Market Volume (K) By Region

Figure 29: Global cgt drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global cgt drugs Market Value (USD Million) By Region

Figure 37: Global cgt drugs Market Share (%) By: Regions (2032)

Figure 38: Global cgt drugs Market Volume (K) By Region

Figure 39: Global cgt drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global cgt drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global cgt drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global cgt drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global cgt drugs Market Value (USD Million) By Region

Table 14: Global cgt drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global cgt drugs Market Volume (K) By Region

Table 31: Global cgt drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global cgt drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global cgt drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global cgt drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Janssen Biotech Basic Information And Sales Area

Table 52: Janssen Biotech. Products Portfolio

Table 53: Celgene Corporation Basic Information And Sales Area

Table 54: Celgene Corporation. Products Portfolio

Table 55: Juno Therapeutics Basic Information And Sales Area

Table 56: Juno Therapeutics. Products Portfolio

Table 57: Kite Pharma Basic Information And Sales Area

Table 58: Kite Pharma. Products Portfolio

Table 59: Novartis Basic Information And Sales Area

Table 60: Novartis. Products Portfolio

Table 61: Spark Therapeutics Basic Information And Sales Area

Table 62: Spark Therapeutics. Products Portfolio

Table 63: Amgen Basic Information And Sales Area

Table 64: Amgen. Products Portfolio

Table 65: Bluebird Bio Basic Information And Sales Area

Table 66: Bluebird Bio. Products Portfolio

Table 67: GSK Basic Information And Sales Area

Table 68: GSK. Products Portfolio

Table 69: Orchard Therapeutics Basic Information And Sales Area

Table 70: Orchard Therapeutics. Products Portfolio

Table 71: Sequoia Basic Information And Sales Area

Table 72: Sequoia. Products Portfolio

Table 73: Fosun Kite Biotechnology Basic Information And Sales Area

Table 74: Fosun Kite Biotechnology. Products Portfolio

Table 75: Sunway Biotech Basic Information And Sales Area

Table 76: Sunway Biotech. Products Portfolio

Table 77: SiBiono Basic Information And Sales Area

Table 78: SiBiono. Products Portfolio

Table 79: Segway Basic Information And Sales Area

Table 80: Segway. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global cgt drugs Market Value (USD Million) By Region

Table 90: Global cgt drugs Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Types

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Types

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Types

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 106: Global cgt drugs Market Volume (K) By Region

Table 107: Global cgt drugs Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Types

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Types

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Types

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

cgt drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 billion
Revenue forecast in 2033	45.88 billion
Growth rate	CAGR of 17.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Janssen Biotech; Celgene Corporation; Juno Therapeutics; Kite Pharma; Novartis; Spark Therapeutics; Amgen; Bluebird Bio; GSK; Orchard Therapeutics; Sequoia; Fosun Kite Biotechnology; Sunway Biotech; SiBiono; Segway
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options